Abby Lindenberg: Florida is the next medtech hub
Key points:
- • caa CEO and Founder Abby Lindenberg joined the Medtech World summit to argue that Florida medtech has crossed from capital attraction into full ecosystem creation.
- • Florida deployed just over $1 billion in life sciences venture capital in 2025 — and is on pace to more than double that figure in 2026.
- • Deal activity like Omeza Holdings’ $8.5 million Series A signals that Florida medtech is generating investment-ready companies across the state, not just in legacy hubs.
May 2026 — At the Medtech World summit, caa CEO and Founder Abby Lindenberg made the case for Florida’s rise as a medical technology hub in the United States. Speaking alongside industry leaders and investors, Lindenberg identified the state as one of the most compelling and underappreciated opportunities in U.S. healthcare investment today.
Join us at caa’s upcoming leadership summits! These premier events bring together hundreds of public and private sector leaders to discuss the challenges and opportunities for businesses and investors. Find the next summit in a city near you!
“Florida is at a fascinating inflection point when it comes to healthcare innovation,” said Lindenberg while kicking off the panel discussion. “For years, the conversation around medtech has centered on cities like Boston, Silicon Valley, or Minneapolis — but over the past several years, something meaningful has started to shift.”
Florida builds its own ecosystem
For years, the Florida medtech conversation centered on what the state could attract: talent, capital, and relocated companies. But as the state’s broader healthcare infrastructure has developed, research institutions, healthcare systems, manufacturing capacity, and venture investment are beginning to function as a self-sustaining ecosystem.
“What makes this moment especially compelling is that many of the forces reshaping healthcare globally align remarkably well with Florida’s unique strengths,” said Lindenberg.
Mark Glickman, president and CEO of BioFlorida, reinforced the point: Florida deployed just over $1 billion in life sciences venture capital in 2025. Year to date in 2026, the figure stands at $900 million — and Glickman projects the full-year total will at least double last year’s haul. Critically, that growth concentrates at the Series A and Series B stages, where business models and scalability are established.
The forces reshaping global healthcare, from AI-enabled diagnostics to remote monitoring, neurotechnology, precision medicine, and decentralized care delivery, align directly with Florida’s structural advantages: the third-largest and fastest-growing state population, a disproportionately older demographic, expanding academic medical centers, and an active state-level investment vehicle in the Florida Opportunity Fund.
Deal flow confirms the shift
One example of the wave of venture interest is Sarasota-based Omeza Holdings. The company, which holds an FDA-cleared regenerative wound care product already in the U.S. market, raised $8.5 million in Series A funding this spring. It is a commercial-stage deal — growth capital, not de-risking capital — and it closed outside any traditional medtech hub. That geographic distribution is the marker of a maturing ecosystem.
For executives and investors still discovering Florida’s potential in the medtech space, Lindenberg’s message at the summit was direct: the infrastructure is built, the capital is moving, and the window for early positioning is narrowing.
Want more? Read the Invest: Palm Beach report.
